Laboratorios Farmaceuticos Rovi, S.A. (OTCPK:LABFF) Q2 2025 Earnings Conference Call July 24, 2025 4:00 AM ET
Company Participants
Javier López-Belmonte Encina – First Deputy Chairman, GM of Industrial Operations & CFO
Juan Encina – Chairman & CEO
Marta Campos Martinez – Head of Investor Relations
Javier López-Belmonte Encina
Good morning to everybody. Thank you for joining us today for our conference on the ROVI’s First Half 2025 Financial Results, which will start in a moment. I am Javier Lopez-Belmonte, ROVI’s Deputy Chairman and Chief Financial Officer. Joining me on today’s call are Juan Lopez-Belmonte, ROVI’s Chairman and CEO; and Marta Campos, our Head of Finance.
The presentation will be followed by a Q&A session. Therefore, if you want to ask any questions during the presentation, please do not hesitate to send them through the question button on the platform.
Before we begin, let me remind you that the information presented in this call contains forward-looking statements based on our current beliefs and expectations. Actual results could materially differ due to the known and unknown risks, uncertainties and other factors, and we undertake no obligation to update or revise any of these statements. With that, I thank you for your presence here today, and I will now hand the presentation over to Juan Lopez-Belmonte. Please Juan, go ahead.
Juan Encina
Thank you, Javier, and good morning to everyone in the call. Since the pandemic, we’ve been steadily investing to build the foundations of our future. 2025 is a transition year for us. We believe it’s essential to continue investing, and that conviction has made us more resilient, more focused and better positioned for sustainable growth.
We are at an inflection point. The progress we’ve made, combined with improving market conditions put us in a strong position for long-term success. In this context, our operating revenue
#Laboratorios #Farmaceuticos #Rovi #S.A #LABFF #Earnings #Call #Transcript